INTRODUCTION
Prostate cancer (PCa) is the second leading cause of death from cancer in men in the United States (1).
The vast majority of men dying of PCa succumb to metastatic, castration-resistant disease. Among the reasons to image PCa, including initial staging, therapeutic monitoring, guiding focal therapies and determining the location of recurrence after prostatectomy, one elusive but important goal is to image with a view to distinguishing indolent from aggressive disease. While no single marker is capable of providing that distinction, the prostate-specific membrane antigen (PSMA), a type II integral membrane protein over-expressed on prostate tumors, provides a step in that direction. Both disease-free survival and time to prostate-specific antigen (PSA) progression are decreased in patients with elevated levels of PSMA within their tumors (2, 3) . PSMA expression has long been associated with androgenindependent disease (4). Recently Evans et al. demonstrated that a positron-emitting version of the anti-PSMA monoclonal antibody (mAb) J591 (5) was able to leverage PSMA expression into a noninvasive biomarker of androgen receptor signaling (6) .
Several modalities have been applied to imaging PCa, but to study PSMA at high sensitivity in vivo others and we have focused on the radionuclide and optical molecular imaging techniques (7 -18). PCa has not succumbed as readily to molecular imaging as other solid tumors as it is not easily visualized on positron emission tomography (PET) with [ 5 agents have been developed for PCa, including radiolabeled versions of choline (20, 21) (25) , as well as a variety of radiolabeled antibodies specific for PSMA (26 -29) , (6) , with several beginning to appear in clinical trials.
We have previously reported the development of N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-
18 F]DCFBC (9) , with which we have initiated a Phase 1 trial (30 analogy to a radioiodinated PSMA-binding ligand that we previously reported, which demonstrated high uptake within PSMA+ tumor and fast clearance from non-target tissues (11) .
RESULTS
Chemical and Radiochemical Syntheses. The tosylate salt of 1, previously described by us (10), was reacted with F-Py-TFP (31) to generate fluoropyridyl urea 2. Deprotection afforded DCFPyL (3) in 81%
yield (Figure 1 Table 3 that were not assigned a time-integrated activity coefficient reflects cross-fire photon contribution from organs that were Antibodies (53), (6) , (27) and antibody fragments (54) , aptamers (55) and low molecular weight PSMAbinding affinity agents (56) , (9), (13), (18), (57) 24 (m, 2H), 3.42 (m, 2H), 2.49 (m, 2H), 2.15 (m, 1H), 1.87-2.00 (m, 2H), 1.64-1.80 (m, 3H), 1.47 (m, 2H) concentration at which enzyme activity was inhibited by 50%. Assays were performed in triplicate with the entire inhibition study being repeated at least once to confirm affinity and mode of inhibition. Enzyme inhibitory constants (K i values) were generated using the Cheng-Prusoff conversion (62, 63) .
Data analysis was performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, California). 
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